170 related articles for article (PubMed ID: 24431404)
21. Naringin, a natural dietary compound, prevents intestinal tumorigenesis in Apc (Min/+) mouse model.
Zhang YS; Li Y; Wang Y; Sun SY; Jiang T; Li C; Cui SX; Qu XJ
J Cancer Res Clin Oncol; 2016 May; 142(5):913-25. PubMed ID: 26702935
[TBL] [Abstract][Full Text] [Related]
22. The threshold level of adenomatous polyposis coli protein for mouse intestinal tumorigenesis.
Li Q; Ishikawa TO; Oshima M; Taketo MM
Cancer Res; 2005 Oct; 65(19):8622-7. PubMed ID: 16204028
[TBL] [Abstract][Full Text] [Related]
23. Profound Chemopreventative Effects of a Hydrogen Sulfide-Releasing NSAID in the APCMin/+ Mouse Model of Intestinal Tumorigenesis.
Paul-Clark M; Elsheikh W; Kirkby N; Chan M; Devchand P; Agbor TA; Flannigan KL; Cheadle C; Freydin M; Ianaro A; Mitchell JA; Wallace JL
PLoS One; 2016; 11(2):e0147289. PubMed ID: 26910063
[TBL] [Abstract][Full Text] [Related]
24. Recurrence of cervical cancer in mice after selective estrogen receptor modulator therapy.
Spurgeon ME; Chung SH; Lambert PF
Am J Pathol; 2014 Feb; 184(2):530-40. PubMed ID: 24418098
[TBL] [Abstract][Full Text] [Related]
25. Estrogen receptor-beta as a potential target for colon cancer prevention: chemoprevention of azoxymethane-induced colon carcinogenesis by raloxifene in F344 rats.
Janakiram NB; Steele VE; Rao CV
Cancer Prev Res (Phila); 2009 Jan; 2(1):52-9. PubMed ID: 19139018
[TBL] [Abstract][Full Text] [Related]
26. Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells.
Eisen SF; Brown HA
Mol Pharmacol; 2002 Oct; 62(4):911-20. PubMed ID: 12237338
[TBL] [Abstract][Full Text] [Related]
27. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells.
Dardes RC; Schafer JM; Pearce ST; Osipo C; Chen B; Jordan VC
Gynecol Oncol; 2002 Jun; 85(3):498-506. PubMed ID: 12051881
[TBL] [Abstract][Full Text] [Related]
28. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.
Overk CR; Peng KW; Asghodom RT; Kastrati I; Lantvit DD; Qin Z; Frasor J; Bolton JL; Thatcher GR
ChemMedChem; 2007 Oct; 2(10):1520-6. PubMed ID: 17654759
[TBL] [Abstract][Full Text] [Related]
29. MET Signaling Mediates Intestinal Crypt-Villus Development, Regeneration, and Adenoma Formation and Is Promoted by Stem Cell CD44 Isoforms.
Joosten SPJ; Zeilstra J; van Andel H; Mijnals RC; Zaunbrecher J; Duivenvoorden AAM; van de Wetering M; Clevers H; Spaargaren M; Pals ST
Gastroenterology; 2017 Oct; 153(4):1040-1053.e4. PubMed ID: 28716720
[TBL] [Abstract][Full Text] [Related]
30. Raloxifene inhibits adipose tissue inflammation and adipogenesis through Wnt regulation in ovariectomized rats and 3 T3-L1 cells.
Shen HH; Yang CY; Kung CW; Chen SY; Wu HM; Cheng PY; Lam KK; Lee YM
J Biomed Sci; 2019 Aug; 26(1):62. PubMed ID: 31470850
[TBL] [Abstract][Full Text] [Related]
31. Raloxifene, a selective estrogen receptor modulator, induces mitochondria-mediated apoptosis in human endometrial carcinoma cells.
Morishima S; Shibata MA; Ohmichi M; Otsuki Y
Med Mol Morphol; 2008 Sep; 41(3):132-8. PubMed ID: 18807138
[TBL] [Abstract][Full Text] [Related]
32. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
Jacoby RF; Cole CE; Tutsch K; Newton MA; Kelloff G; Hawk ET; Lubet RA
Cancer Res; 2000 Apr; 60(7):1864-70. PubMed ID: 10766173
[TBL] [Abstract][Full Text] [Related]
33. Raloxifene in breast cancer prevention.
Gennari L; Merlotti D; Paola VD; Nuti R
Expert Opin Drug Saf; 2008 May; 7(3):259-70. PubMed ID: 18462184
[TBL] [Abstract][Full Text] [Related]
34. Silibinin suppresses spontaneous tumorigenesis in APC min/+ mouse model by modulating beta-catenin pathway.
Rajamanickam S; Kaur M; Velmurugan B; Singh RP; Agarwal R
Pharm Res; 2009 Dec; 26(12):2558-67. PubMed ID: 19779968
[TBL] [Abstract][Full Text] [Related]
35. The SERM raloxifene improves diaphyseal fracture healing in mice.
Spiro AS; Khadem S; Jeschke A; Marshall RP; Pogoda P; Ignatius A; Amling M; Beil FT
J Bone Miner Metab; 2013 Nov; 31(6):629-36. PubMed ID: 23546819
[TBL] [Abstract][Full Text] [Related]
36. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor.
Oshima M; Murai N; Kargman S; Arguello M; Luk P; Kwong E; Taketo MM; Evans JF
Cancer Res; 2001 Feb; 61(4):1733-40. PubMed ID: 11245490
[TBL] [Abstract][Full Text] [Related]
37. The selective oestrogen receptor modulators idoxifene and raloxifene have fundamentally different cell-specific oestrogen-response element (ERE)-dependent/independent mechanisms in vitro.
Nuttall ME; Fisher PW; Suva LJ; Gowen M
Eur J Cancer; 2000 Sep; 36 Suppl 4():S63-4. PubMed ID: 11056323
[TBL] [Abstract][Full Text] [Related]
38. Supplementation with phytoestrogens and insoluble fibers reduces intestinal carcinogenesis and restores ER-β expression in Apc-driven colorectal carcinogenesis.
Luceri C; Femia AP; Tortora K; D'Ambrosio M; Fabbri S; Fazi M; Caderni G
Eur J Cancer Prev; 2020 Jan; 29(1):27-35. PubMed ID: 31651566
[TBL] [Abstract][Full Text] [Related]
39. Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis.
Zeilstra J; Joosten SP; Dokter M; Verwiel E; Spaargaren M; Pals ST
Cancer Res; 2008 May; 68(10):3655-61. PubMed ID: 18483247
[TBL] [Abstract][Full Text] [Related]
40. Modulation of intracellular beta-catenin localization and intestinal tumorigenesis in vivo and in vitro by sphingolipids.
Schmelz EM; Roberts PC; Kustin EM; Lemonnier LA; Sullards MC; Dillehay DL; Merrill AH
Cancer Res; 2001 Sep; 61(18):6723-9. PubMed ID: 11559543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
